Regentis Biomaterials Advances GelrinC® Clinical Trials and Expands Commercialization Efforts

Regentis Biomaterials, a regenerative medicine company, has reported significant progress in its first half of 2026 financial results and provided an update on its key clinical and corporate initiatives. The company has advanced its pivotal Phase III GelrinC® clinical trial, with 43 patients treated and an expected completion of 80 patients by the end of the year.

GelrinC®, Regentis' lead product, is a cell-free, off-the-shelf hydrogel implant designed to treat painful and debilitating injuries to focal articular knee cartilage. The company has expanded its U.S. clinical site network, adding leading orthopedic centers across the country. According to CEO Ehud Geller, the current pace of enrollment suggests full enrollment of 80 patients in the U.S. pivotal trial will be achieved by year-end 2026, compared to the previous expectation of the third quarter.

In Europe, where GelrinC® has CE Mark approval, Regentis is engaging with physicians and clinical centers to support the adoption of the procedure. The company has also expanded its European clinical network, adding sites in Italy, Germany, Serbia, Slovenia, and Romania. These efforts are part of the company's broader strategy to prepare for commercialization in the region.

Regentis has also made strides in manufacturing capabilities. The company developed a new solvent-free manufacturing process that increases GelrinC® production yield by 400%. This process has received regulatory approval from the European Notified Body, supporting the scale-up of manufacturing for anticipated commercial requirements and future market expansion.

Regentis has also published peer-reviewed data demonstrating the long-term durability of cartilage repair with GelrinC®. The results, published in the peer-reviewed journal Cartilage, used quantitative MOCART assessment of the complete follow-up dataset from the GelrinC® Phase II study. The data showed durable morphological cartilage repair through two years, supporting the quality and durability of regenerated tissue.

Financially, Regentis reported a net loss of approximately $2.6 million for the first half of 2026, compared to $3.2 million in the same period in 2025. The improvement in net loss primarily reflected a significant reduction in finance expenses, partially offset by increased research and development and general and administrative expenses. The company also completed a $6.5 million private placement, bringing its cash and cash equivalents to approximately $9.0 million as of June 30, 2026.

Geller commented, "During the first half of 2026, we continued to advance GelrinC® on multiple fronts as we build toward important clinical and commercial milestones in the U.S. and Europe. Interest in GelrinC® from physicians, patients, and clinical centers continues to build, and we are encouraged by the engagement we are seeing as we expand the number of active clinical sites in the United States and Europe."

With the completion of the private placement and the continued progress in clinical and manufacturing efforts, Regentis remains well-positioned to pursue its mission of developing innovative tissue repair solutions that restore health and enhance the quality of life for patients suffering from painful and debilitating injuries.